Ascendis Pharma A (ASND) Revenue (2014 - 2026)
Ascendis Pharma A (ASND) posted Revenue of $288.7 million for Q1 2026, down 40.44% sequentially from $484.8 million in Q4 2025, and up 171.87% YoY from $106.2 million in Q1 2025.
Ascendis Pharma A (ASND) Revenue (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Revenue for 13 years, with the latest figure at $288.7 million in Q1 2026.
- Quarterly Revenue rose 171.87% year-over-year to $288.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 122.73% YoY) and the FY2025 annual result came in at $838.3 million, up 93.32% from the prior year.
- Revenue fell to $288.7 million in Q1 2026 per ASND's latest filing, from $484.8 million in the prior quarter.
- Over five years, Revenue peaked at $484.8 million in Q4 2025 and troughed at $6.6 million in Q2 2022.
- A 5-year average of $139.1 million and a median of $63.5 million in 2024 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2023: Revenue slumped 76.29% in 2022, then soared 1294.35% in 2023.
- Over 5 years, Revenue stood at $23.4 million in 2022, then soared by 1294.35% to $325.7 million in 2023, then grew by 1.7% to $331.2 million in 2024, then surged by 46.35% to $484.8 million in 2025, then sank by 40.44% to $288.7 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $288.7 million, $484.8 million, and $249.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 288.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 288.71 Mn |
| Dec 31, 2025 | 484.77 Mn |
| Sep 30, 2025 | 249.75 Mn |
| Jun 30, 2025 | 178.90 Mn |
| Mar 31, 2025 | 106.19 Mn |
| Dec 31, 2024 | 331.25 Mn |
| Sep 30, 2024 | 63.51 Mn |
| Jun 30, 2024 | 38.77 Mn |
| Mar 31, 2024 | 104.18 Mn |
| Dec 31, 2023 | 325.70 Mn |
| Sep 30, 2023 | 52.29 Mn |
| Jun 30, 2023 | 51.61 Mn |
| Mar 31, 2023 | 36.05 Mn |
| Dec 31, 2022 | 23.36 Mn |
| Sep 30, 2022 | 15.42 Mn |
| Jun 30, 2022 | 6.57 Mn |
| Mar 31, 2022 | 7.66 Mn |
| Dec 31, 2021 | 98.53 Mn |
| Sep 30, 2021 | 1.31 Mn |
| Jun 30, 2021 | 1.23 Mn |